Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

19.05USD
9:37am EST
Change (% chg)

$0.44 (+2.36%)
Prev Close
$18.61
Open
$18.39
Day's High
$19.24
Day's Low
$18.36
Volume
1,257,471
Avg. Vol
4,676,147
52-wk High
$38.30
52-wk Low
$10.85

Latest Key Developments (Source: Significant Developments)

Fda Accepts Biologics License Application For Fremanezumab With Priority Review
8:00am EST 

Dec 18 (Reuters) - Teva Pharmaceutical Industries Ltd ::FDA ACCEPTS BIOLOGICS LICENSE APPLICATION FOR FREMANEZUMAB WITH PRIORITY REVIEW FOR PREVENTION OF MIGRAINE AND GRANTS FAST TRACK DESIGNATION FOR CLUSTER HEADACHE DEVELOPMENT PROGRAM.TEVA PHARMACEUTICAL INDUSTRIES - TEVA ANTICIPATES LAUNCHING ANTI-CGRP PRODUCT IN U.S. FOR PREVENTION OF MIGRAINE IN 2018.TEVA PHARMACEUTICAL INDUSTRIES - FREMANEZUMAB ACHIEVED STATISTICALLY SIGNIFICANT RESULTS ACROSS ALL TRIAL ENDPOINTS.TEVA PHARMACEUTICAL INDUSTRIES LTD - STUDIES FOR PHASE III ENFORCE CLINICAL RESEARCH PROGRAM ARE EXPECTED TO CONCLUDE IN EARLY 2019.TEVA PHARMACEUTICAL INDUSTRIES - CO HAS ALSO INITIATED A FREMANEZUMAB PHASE II CLINICAL PROGRAM FOR TREATMENT OF POST-TRAUMATIC HEADACHE DISORDER.  Full Article

Teva Announces Exclusive Launch Of Generic Viread® In The United States
Friday, 15 Dec 2017 09:00am EST 

Dec 15 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES EXCLUSIVE LAUNCH OF GENERIC VIREAD® IN THE UNITED STATES.TEVA ANNOUNCES EXCLUSIVE LAUNCH OF GENERIC VIREAD® IN THE UNITED STATES.TEVA PHARMACEUTICAL INDUSTRIES LTD - ANNOUNCED EXCLUSIVE LAUNCH OF GENERIC VIREAD TABLETS 300 MG IN U.S..  Full Article

Teva Pharm CEO says cost-cutting won't hurt competitiveness
Thursday, 14 Dec 2017 09:55am EST 

Dec 14 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA PHARM CEO: EXPECTS U.S. GENERIC PRICES OVERALL TO FALL IN 2018.TEVA PHARM CEO: I'M COMMITTED TO MAINTAINING HEADQUARTERS IN ISRAEL.TEVA PHARM CEO: WE HAVE NO PLANS OF RAISING NEW EQUITY SHORT TERM OR LONG TERM.TEVA PHARM CEO: TEVA WILL REMAIN COMPETITIVE DESPITE COST-CUTTING MEASURES.  Full Article

Teva Pharm CEO says company does not plan to raise equity
Thursday, 14 Dec 2017 08:34am EST 

Dec 14 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA PHARM CEO: COMPANY DOES NOT PLAN TO RAISE EQUITY.TEVA PHARM CEO: WILL USE CASH FLOW TO PAY DOWN DEBT IN COMING YEARS, INITIALLY WILL FOCUS ON BANK DEBT.TEVA TO CUT 1,700 JOBS IN ISRAEL, CLOSE JERUSALEM MANUFACTURING PLANT BY END OF 2019 -COMPANY OFFICIAL.TEVA PHARM CEO: REVENUE ON PROFITABLE PRODUCT LINES WON'T BE IMPACTED BY RESTRUCTURING.  Full Article

Teva Announces Restructuring Plan And Measures To Improve Its Business And Financial Performance
Thursday, 14 Dec 2017 07:03am EST 

Dec 14 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES RESTRUCTURING PLAN AND ADDITIONAL MEASURES TO IMPROVE ITS BUSINESS AND FINANCIAL PERFORMANCE.TEVA PHARMACEUTICAL INDUSTRIES LTD - WORKFORCE TO BE REDUCED BY OVER 25%.TEVA PHARMACEUTICAL INDUSTRIES LTD - TOTAL COST BASE TO BE REDUCED BY $3 BILLION BY END OF 2019.TEVA PHARMACEUTICAL INDUSTRIES LTD - DIVIDEND SUSPENDED ON ORDINARY SHARES AND ADSS.TEVA PHARMACEUTICAL INDUSTRIES LTD SAYS REDUCTION OF 14,000 POSITIONS GLOBALLY OVER NEXT TWO YEARS.TEVA PHARMACEUTICAL INDUSTRIES LTD - EXPECTS TO RECORD A RESTRUCTURING CHARGE AS A RESULT OF IMPLEMENTATION OF PLAN IN 2018 OF AT LEAST $700 MILLION.TEVA PHARMACEUTICAL INDUSTRIES LTD - MORE THAN HALF OF REDUCTION IS EXPECTED TO BE ACHIEVED BY END OF 2018.TEVA PHARMACEUTICAL INDUSTRIES LTD - MAJORITY OF WORKFORCE REDUCTIONS ARE EXPECTED TO OCCUR IN 2018.TEVA PHARMACEUTICAL INDUSTRIES LTD - COMPANY WILL CONTINUE TO REVIEW POTENTIAL FOR ADDITIONAL DIVESTMENT OF NON-CORE ASSETS.TEVA PHARMACEUTICAL INDUSTRIES LTD - "IN 2018, WE EXPECT TO SECURE SUCCESSFUL LAUNCHES OF AUSTEDO AND FREMANEZUMAB".TEVA PHARMACEUTICAL INDUSTRIES - CO'S ANNUAL BONUS FOR 2017 WILL NOT BE PAID AS CO'S FINANCIAL RESULTS ARE SIGNIFICANTLY BELOW ORIGINAL GUIDANCE FOR YEAR.TEVA PHARMACEUTICAL - LAUNCHING A COMPREHENSIVE RESTRUCTURING PLAN, "CRUCIAL TO RESTORING" FINANCIAL SECURITY AND STABILIZING BUSINESS.  Full Article

Mylan Says Teva Has Dismissed Its Pending Litigation Against Co
Monday, 11 Dec 2017 12:16pm EST 

Dec 11 (Reuters) - Mylan Nv ::MYLAN NV - ANNOUNCED THAT TEVA HAS DISMISSED ITS PENDING DISTRICT COURT LITIGATION AGAINST MYLAN.MYLAN NV - TEVA HAS AGREED TO WITHDRAW IRISH EQUIVALENT TO THE PATENTS FROM RECENTLY FILED PROCEEDING IN IRELAND.MYLAN NV - TEVA'S PENDING LITIGATION AGAINST CO IS REGARDING CO'S GLATIRAMER ACETATE INJECTION 40 MG/ML, FIRST GENERIC VERSION OF COPAXONE 40 MG/ML.  Full Article

Teva Announces Exclusive Launch Of Generic Viagra Tablets In The United States
Monday, 11 Dec 2017 09:13am EST 

Dec 11 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES EXCLUSIVE LAUNCH OF GENERIC VIAGRA® TABLETS IN THE UNITED STATES.TEVA PHARMACEUTICAL INDUSTRIES LTD - ‍EXCLUSIVE LAUNCH OF ITS GENERIC VIAGRA TABLETS IN U.S​.  Full Article

Teva Pharmaceutical may cut up to 10,000 jobs globally -Bloomberg
Friday, 8 Dec 2017 10:30am EST 

Dec 8 (Reuters) - :TEVA PHARMACEUTICAL MAY CUT UP TO 10,000 JOBS GLOBALLY -BLOOMBERG.  Full Article

Moody's Says Pharma Manufacturers, Distributors Face Rising Risks Related To U.S. Opioid Crisis
Thursday, 30 Nov 2017 10:06am EST 

Nov 30 (Reuters) - Moody's::MOODY'S SAYS PHARMA MANUFACTURERS AND DISTRIBUTORS FACE RISING RISKS RELATED TO U.S. OPIOID CRISIS.MOODY'S ON U.S. OPIOID CRISIS - BRANDED,GENERIC DRUG COS,DRUG DISTRIBUTORS WILL BE INCREASINGLY EXPOSED TO DECLINING PRODUCT SALES, RISING LEGAL RISKS.MOODY'S SAYS ABILITY OF PHARMA MANUFACTURERS,DISTRIBUTORS TO FACE RISKS RELATED TO U.S. OPIOID CRISIS WILL DEPEND ON SCALE,DIVERSITY,LIQUIDITY, OTHERS.MOODY'S SAYS AMONG COS,J&J IS SUFFICIENTLY STRONG TO ABSORB U.S. OPIOID-RELATED RISKS, WHILE ENDO PHARMACEUTICALS & TEVA HAVE MORE LIMITED FLEXIBILITY.  Full Article

Teva Appoints Michael McClellan as CFO
Monday, 27 Nov 2017 09:00am EST 

Nov 27 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES NEW ORGANIZATION STRUCTURE AND LEADERSHIP CHANGES.TEVA PHARMACEUTICAL INDUSTRIES LTD - ‍COMMERCIAL BUSINESS WILL NO LONGER HAVE TWO SEPARATE GLOBAL GROUPS FOR GENERICS AND SPECIALTY MEDICINES​.TEVA PHARMACEUTICAL-‍FORMER GENERIC RESEARCH AND DEVELOPMENT, SPECIALTY RESEARCH AND DEVELOPMENT ORGANIZATIONS TO BE COMBINED INTO 1 GLOBAL GROUP WITH OVERALL RESPONSIBILITY FOR ALL RESEARCH AND DEVELOPMENT ACTIVITIES.TEVA - ‍AS A RESULT OF THE CHANGES, MICHAEL HAYDEN, ROB KOREMANS AND DIPANKAR BHATTACHARJEE WILL RETIRE FROM TEVA, EFFECTIVE DECEMBER 31​.TEVA PHARMACEUTICAL - ‍ COMMERCIAL BUSINESS WILL BE INTEGRATED INTO ONE COMMERCIAL ORGANIZATION​.TEVA - ‍MICHAEL MCCLELLAN APPOINTED EVP, CFO,WILL OVERSEE FINANCE GROUP, BUSINESS DEVELOPMENT, INVESTOR RELATIONS,INFORMATION TECHNOLOGY​.TEVA PHARMA - COMMERCIAL ‍STRUCTURE TO RELY ON 1 SUPPORTING ORGANIZATIONAL INFRASTRUCTURE INCLUDING FINANCE, LEGAL, HR, GLOBAL BRAND & COMMUNICATIONS​.TEVA PHARMACEUTICAL SAYS ‍ALREADY WORKING ON A DETAILED RESTRUCTURING PLAN FOR TEVA AND WILL SHARE IT IN MID-DECEMBER​.TEVA PHARMACEUTICAL INDUSTRIES LTD - ‍PRIOR TO JOINING TEVA, MICHAEL MCCLELLAN WAS U.S. CFO AT SANOFI​.  Full Article

BRIEF-Fda Accepts Biologics License Application For Fremanezumab With Priority Review

* FDA ACCEPTS BIOLOGICS LICENSE APPLICATION FOR FREMANEZUMAB WITH PRIORITY REVIEW FOR PREVENTION OF MIGRAINE AND GRANTS FAST TRACK DESIGNATION FOR CLUSTER HEADACHE DEVELOPMENT PROGRAM